Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

231.60DKK
24 Mar 2017
Change (% chg)

kr.-2.60 (-1.11%)
Prev Close
kr.234.20
Open
kr.231.20
Day's High
kr.234.30
Day's Low
kr.230.40
Volume
3,984,684
Avg. Vol
3,902,365
52-wk High
kr.384.80
52-wk Low
kr.218.20

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.43
Market Cap(Mil.): kr.466,109.81
Shares Outstanding(Mil.): 2,012.56
Dividend: 4.60
Yield (%): 3.28

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 15.48 29.17 29.94
EPS (TTM): 14.96 -- --
ROI: 75.08 13.48 13.01
ROE: 82.23 14.39 14.16

EMA panel backs Novo Nordisk's hemophilia B drug

A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's hemophilia B drug.

Mar 24 2017

UPDATE 1-EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

Mar 24 2017

EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

Mar 24 2017

BRIEF-EU recommends approval of Novo Nordisk's haemophilia drug

* Recommends approval of Novo Nordisk's Nonacog Beta Pegol drug for treatment of haemophilia

Mar 24 2017

BRIEF-Novo Nordisk gets positive opinion for label update in EU for Tresiba

* The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials

Mar 24 2017

BRIEF-Denmark's Novo Nordisk will not turn into big M&A machine-CEO

March 23 The CEO of Novo Nordisk's, the world's biggest diabetes company, made the following comments at the firm's annual general meeting on Thursday:

Mar 23 2017

BRIEF-Dong Energy to build biogas plant for Novo Nordisk, Novozymes residues

* Says will in cooperation with Bigadan build a large-scale biogas plant

Mar 23 2017

BRIEF-CVS Health to launch reduced RX

* CVS Health Corp says will launch reduced RX, a prescription savings program that will offer discounts on certain medications

Mar 16 2017

Novo Nordisk's new CEO turns to deals to help revive growth

Novo Nordisk's new chief executive is looking at making acquisitions to broaden the Danish drugmaker's product line-up, in a change of tack that reflects a need for fresh sources of growth at the world's biggest diabetes company.

Mar 09 2017

Exclusive: Novo Nordisk in bid for Global Blood Therapeutics - sources

Danish drugmaker Novo Nordisk A/S has approached Global Blood Therapeutics Inc , a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.

Mar 08 2017

More From Around the Web

Earnings vs. Estimates